^
    2years
    The CD47-targeting antibody ZL-1201 enhances anti-tumor activity of standard of care therapeutic antibodies by promoting phagocytosis in hematologic and solid tumor models (AACR 2022)
    These include rituximab for CD20-expressing lymphomas, trastuzumab for HER2-amplified cancers, and cetuximab for EGFR-driven solid tumors. This study indicates that ZL-1201 may combine with a broad range of SoC mAbs to enhance their clinical benefit across a variety of hematologic and solid tumor indications. ZL-1201 is under Ph1 clinical investigation (NCT04257617).
    Preclinical • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • CD20 (Membrane Spanning 4-Domains A1) • CD47 (CD47 Molecule) • FCGR2A (Fc fragment of IgG receptor IIa) • FCGR2B (Fc Fragment Of IgG Receptor IIb) • SIRPA (Signal Regulatory Protein Alpha)
    |
    HER-2 amplification • CD20 expression
    |
    Herceptin (trastuzumab) • Erbitux (cetuximab) • Rituxan (rituximab) • ZL-1201
    3years
    [VIRTUAL] ZL-1201, a differentiated CD47 therapeutic antibody with improved hematological safety profile (AACR 2021)
    Thus, ZL-1201 treatment represents an effective CD47-targeting therapy with improved hematological safety consequences. A Ph1 dose escalation study to assess the safety of ZL-1201 is currently ongoing in patients with solid tumors, and future combination studies are planned for both hematologic and solid tumor indications.
    Clinical
    |
    CD47 (CD47 Molecule)
    |
    CD47 overexpression
    |
    ZL-1201